We compared patients with ( n = 12 ) or without AST ( n = 2,184 ) regarding baseline , clinical , and procedural characteristics and antithrombotic treatment strategies ( choice of P2Y12 inhibitor , post-primary PCI bivalirudin infusion dose [ 0.25 mg/kg/h , or BIV-LOW ] vs. [ 1.75 mg/kg/h , or BIV-PCI ] vs. heparin GPI ) .